A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome

Oliver Groß(Universitätsmedizin Göttingen), Markus Feldkoetter(Universitätsmedizin Göttingen), Sabine Ponsel(University Hospital Münster), H. Zappel(Universitätsmedizin Göttingen), Peter F. Hoyer(Essen University Hospital), Lisa Loechtermann, Lutz T. Weber(University Hospital Cologne), Sabine König(University Hospital Münster), Clifford E. Kashtan(University of Minnesota Medical Center), Brigitta Kranz, Baerbel Lange‐Sperandio(Ludwig-Maximilians-Universität München), Michael Pohl, Anne-Kristin Vogt-Weigeldt, Britta Hoecker(University Hospital Heidelberg), Rasmus Ehren(University Hospital Cologne), Jens Koenig, Markus Harden(Universitätsmedizin Göttingen), Julia Thumfart(Charité - Universitätsmedizin Berlin), Christian Lerch(Medizinische Hochschule Hannover), Gesa Schalk, Max C. Liebau, Ulrike Jacoby(Jena University Hospital), Nicole Meyer, Tim Friede(Universitätsmedizin Göttingen), S. Klaiber, Matthias Kettwig(Friedrich-Alexander-Universität Erlangen-Nürnberg), Lars Pape(University of Duisburg-Essen), Mirja Wedekin, Carsten Bramlage, Joseph Sonntag, Matthias Hansen(Friedrich-Alexander-Universität Erlangen-Nürnberg), Bernd Höppe(University of Bonn), Jenny Frese, Jan Boeckhaus(University Medical Center), Kay Latta, Therese Jungraithmayr, Michael Koziolek, Reinhard Hilgers, Tanja Albrecht-Nock, Ulrike John(Jena University Hospital), Martin Konrad(University Hospital Münster), Jutta Gellermann(Charité - Universitätsmedizin Berlin), Hagen Staude(University of Rostock), Katrin Mueller, Burkhard Tönshoff(Heidelberg University), Frauke Weber(University of Cologne), Henry Fehrenbach, Matthias Galiano(Friedrich-Alexander-Universität Erlangen-Nürnberg), Michaela Geßner(Children's Hospital at Westmead), Ralf A. Husain
Kidney International
January 17, 2020
10.1016/j.kint.2019.12.015
Cited by 151

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Multiorgan and Renal Tropism of SARS-CoV-2
|New England Journal of Medicine|2020|1.9k
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
X-linked Alport Syndrome
|Journal of the American Society of Nephrology|2000|592
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|573